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ABSTRACT:
&HOOPRWLOLW\DQGLQYDVLRQLQLWLDWHPHWDVWDVLV+RZHYHURQO\DVXESRSXODWLRQRI
FDQFHUFHOOVZLWKLQDWXPRUZLOOXOWLPDWHO\EHFRPHLQYDVLYH'XHWRWKLVVWRFKDVWLF
DQGWUDQVLHQWQDWXUHLQDQH[SHULPHQWDOVHWWLQJPLJUDWLQJDQGLQYDGLQJFHOOVQHHG
WREHLVRODWHGIURPWKHJHQHUDOSRSXODWLRQLQRUGHUWRVWXG\WKHJHQHH[SUHVVLRQ
SUR¿OHVOLQNHGWRWKHVHSURFHVVHV7KLVUHSRUWGHVFULEHVPLFURDUUD\DQDO\VLVRQ51$
GHULYHGIURPPLJUDWHGRULQYDGHGVXESRSXODWLRQVRIWULSOHQHJDWLYHEUHDVWFDQFHU
FHOOVLQD7UDQVZHOOVHWXSDWWZRGLϑHUHQWWLPHSRLQWVGXULQJPRWLOLW\DQGLQYDVLRQ
SUHGHWHUPLQHGDV³HDUO\´DQG³ODWH´LQUHDOWLPHNLQHWLFDVVHVVPHQWV,QYDVLRQDQG
PLJUDWLRQUHODWHGJHQHH[SUHVVLRQVLJQDWXUHVZHUHJHQHUDWHGWKURXJKFRPSDULVRQ
ZLWKQRQLQYDVLYHFHOOVUHPDLQLQJDWWKHXSSHUVLGHRIWKH7UDQVZHOOPHPEUDQHV
/DWHSKDVHVLJQDWXUHVRIERWKLQYDVLRQDQGPLJUDWLRQLQGLFDWHGSRRUSURJQRVLVLQD
VHULHVRIEUHDVWFDQFHUGDWDVHWV)XUWKHUPRUHHYDOXDWLRQRIWKHJHQHVFRQVWLWXWLQJ
WKHSURJQRVWLFLQYDVLRQUHODWHGJHQHVLJQDWXUHUHYHDOHG.USSHOOLNHIDFWRUKLF9) 
DVDSXWDWLYHVXSSUHVVRURILQYDVLYHJURZWKLQEUHDVWFDQFHU1H[WWRORVVLQLQYDVLYH
YVQRQLQYDVLYHFHOOOLQHVKLF9 DOVRVKRZHGVLJQL¿FDQWO\ORZHUH[SUHVVLRQOHYHOV
LQWKH³HDUO\´LQYDVLYHFHOOSRSXODWLRQLQVHYHUDOSXEOLFH[SUHVVLRQGDWDVHWVDQGLQ
FOLQLFDOEUHDVWFDQFHUVDPSOHVZKHQFRPSDUHGWRQRUPDOWLVVXH2YHUH[SUHVVLRQRI
(*)3./)IXVLRQSURWHLQVLJQL¿FDQWO\DOWHUHGPRUSKRORJ\DQGEORFNHGLQYDVLRQDQG
JURZWKRI0'$0%FHOOVin vitro,QDGGLWLRQKLF9H[SUHVVLRQFRUUHODWHGLQYHUVHO\
ZLWKPLWRWLFDFWLYLW\LQFOLQLFDOVDPSOHVLQGLFDWLQJDQWLSUROLIHUDWLYHHϑHFWV
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INTRODUCTION
Breast cancer remains the most frequently diagnosed 
malignancy and the primary cause of cancer-related death 
in women globally [1]. The heterogeneity of this disease, 
both inter- and intratumoral, contributes to its morbidity 
and underlines the necessity for personalized prognostics 
DQG WKHUDSHXWLFV 0HWDVWDVLV PDUNV WKH ¿QDO V\VWHPLF
stage of advanced disease and results from a multistep 
process involving detachment of cells from the primary 
tumor, entry into and survival within the vasculature, 
arrest and exit into distant organ parenchyma, followed 
by formation of micrometastatic lesions, eventually 
developing into overt metastasis [2]. As disseminated 
disease accounts for > 90% of cancer mortality [3], there is 
DQRQJRLQJQHHGIRULGHQWL¿FDWLRQRIUHOHYDQWJHQHVZLWKLQ
this process. 
Local invasive growth represents an initiating event 
predetermining metastatic spread and consists of a highly 
orchestrated interplay of transcriptional and signaling 
changes [1, 4, 5]. Paradoxically however, it has been 
established that only a small fraction of primary tumor 
cells become invasive and ultimately metastatic [2, 6]. 
Moreover, variability in the locoregional distribution of 
invasiveness within individual primary tumors tends to 
LOOXVWUDWHLQWUDWXPRUDOKHWHURJHQHLW\>@$VLJQL¿FDQW
proportion of cancer cell motility and invasion is propelled 
by chemotaxis, whereby cells move directionally along 
a gradient of soluble factors [9, 10]. Although modes 
of collective invasion have been recognized to play an 
important role in the biology of tumor progression, an 
important contribution to this process is added by invasive 
behavior generated on a single-cell basis, driven by 
epithelial-to-mesenchymal transition (EMT) [11].
Genome-wide approaches to elucidate gene 
expression patterns can be applied to identify genes 
HVVHQWLDOO\DVVRFLDWHGZLWKVSHFL¿FELRORJLFDOSKHQRW\SHV
As cell motility and invasion have a stochastic and 
transient nature, in an experimental setting, migrating 
and invading cells need to be isolated from the general 
SRSXODWLRQLQRUGHUWRVWXG\WKHJHQHH[SUHVVLRQSUR¿OHV
linked to these processes [8]. This report describes 
microarray analysis on minute RNA-quantities derived 
from migrated or invaded subpopulations of triple negative 
MDA-MB-231 breast cancer cells in a Transwell set-up 
at two different time points during motility and invasion, 
pre-determined as “early” and “late” in real-time kinetic 
assessments (Fig 1).  Invasion- and migration-related gene 
expression signatures were generated through comparison 
with non-invasive cells, remaining at the upper side of 
the Transwell membranes. Late-phase signatures of both 
invasion and migration indicated poor prognosis in a series 
of breast cancer data sets. Furthermore, evaluation of the 
genes constituting the prognostic invasion-related gene 
signature revealed a differential expression of members 
of the Krüppel-like transcription factor family (KLFs) 
DQGPRUHVSHFL¿FDOO\.USSHOOLNHIDFWRUKLF9) was 
LGHQWL¿HGDVDSRWHQWLDONH\SOD\HULQLQYDVLYHJURZWKRI
breast cancer.
RESULTS
([SUHVVLRQ SUR¿OLQJ RIPLJUDWRU\ DQG LQYDVLYH
EUHDVWWXPRUFHOOV
Initially, to determine the time dependent motion 
kinetics of MDA-MB-231 cells, real-time impedance-
based recording of invasion and migration was performed, 
revealing different phases in both processes (Fig 1). 
After selection of two time points (“early” and “late”), 
RNA from invasive and migratory MDA-MB-231 cells 
was isolated from Transwell membranes and hybridized 
onto an Illumina HumanHT-12 v4 Expression beadchip. 
When comparing gene expressions of migrated vs 
UHIHUHQFHFHOOVZHLGHQWL¿HGDQGXQLTXHDQG
differentially expressed genes at the early and late time 
point respectively. For both time points, approximately 
half of the differentially expressed genes were upregulated 
in the motile cell fraction (respectively 47% and 52%). 
6LPLODU DQDO\VLV RI WKH H[SUHVVLRQ SUR¿OHV RI WKH
invasive cells resulted in 3116 and 1060 unique and 
differentially expressed genes in the early and the late 
time points respectively. Again, for both time points, 
approximately half of the differentially expressed genes 
were upregulated in the invasive cell fraction (respectively 
45% and 50%). Lists of differentially expressed genes are 
provided in the supplementary table S1. GSEA and IPA 
suggest that NFkB-signaling, cell death and attenuated 
cell proliferation are characteristics of early migratory 
cells whereas at later time points, migratory cells show 
evidence of active cell proliferation. Invasive cells 
exhibit a remarkably similar and time point-independent 
ELRORJLFDOSUR¿OHFKDUDFWHUL]HGE\DWWHQXDWHG,QWHUIHURQ
type 1 signaling and active DNA metabolism. Remarkably, 
diverse pathways of DNA-replicaton and repair, double 
strand break repair and damage response were found to 
EHVLJQL¿FDQWO\HQULFKHGLQLQYDVLYHFHOOVVXSSOHPHQWDU\
¿JXUH  'HWDLOHG UHVXOWV LQFOXGLQJ WKH WRSVFRULQJ
QHWZRUNIRUHDFKJHQHOLVWLGHQWL¿HGE\,3$DUHSURYLGHG
in the supplementary table S2.
*HQHUDWLRQRIJHQHVLJQDWXUHVIRUPLJUDWRU\RU
LQYDVLYHEUHDVWFDQFHUFHOOV
Using the nearest shrunken centroid-algorithm, we 
LGHQWL¿HGJHQHVLJQDWXUHVUHSUHVHQWLQJPROHFXODUFKDQJHV
occurring either early or late during the acquisition of a 
motile or invasive cell phenotype. For each condition, 
WKHįYDOXHWKHFRUUHVSRQGLQJFURVVYDOLGDWHGHUURUUDWH
and the number of genes retained in the signatures are 
Oncoscience71www.impactjournals.com/oncoscience
provided in Table 1. The genes constituting the signatures 
are indicated in the respective lists of differentially 
expressed genes (supplementary table S1). When applying 
the early and late invasion gene signatures onto the gene 
H[SUHVVLRQSUR¿OHVIURPDFROOHFWLRQRIEUHDVWFDQFHUFHOO
OLQHVFODVVL¿HGDV³LQYDVLYH´RU³QRQLQYDVLYH´>@ERWK
VLJQDWXUHVDFKLHYHGDVHQVLWLYLW\DQGVSHFL¿FLW\RI
and 58% respectively.
$SSOLFDWLRQRIJHQHVLJQDWXUHVRQEUHDVWFDQFHU
expression series
7RHYDOXDWHWKHFOLQLFDOUHOHYDQFHRIWKHLGHQWL¿HG
gene signatures, each of them was applied onto four gene 
expression data sets, comprising for a total of 979 samples 
from patients with breast cancer. Across all signatures, 
about 48% (range: 47% - 49%) of the samples were 
predicted to exhibit migratory or invasive properties. For 
each signature, the percentage of samples with presumed 
migratory or invasive properties for each data set and 
their range of posterior probabilities (i.e. indication of the 
UREXVWQHVVRIFODVVL¿FDWLRQDUHSURYLGHGLQVXSSOHPHQWDU\
WDEOH6:KHQFRPSDULQJWKHFODVVL¿FDWLRQVREWDLQHGIRU
HDFKRIWKHVLJQDWXUHVZHREVHUYHGVLJQL¿FDQWDJUHHPHQWV
EHWZHHQ WKH FODVVL¿FDWLRQ UHVXOWV DYHUDJH 25 
UDQJH 25V  DOO 3 LQGLFDWLQJ WKDW
migration and invasion are related biological processes 
in breast cancer biology, independent of the evaluated 
WLPHSRLQW:KHQFRPSDULQJWKHFODVVL¿FDWLRQUHVXOWVWR
the molecular subtypes, we observed augmented posterior 
probability scores for all the signatures in basal-like breast 
tumors and attenuated posterior probability scores in 
OXPLQDO$EUHDVWWXPRUV.UXVNDO:DOOLVWHVWDOO3
These results were corroborated by correlation analyses, 
comparing the posterior probability scores obtained for 
each signature with PAM50-derived scores for basal-
like, HER2-enriched, luminal A, luminal B and normal-
like breast cancer. In addition, positive correlations were 
observed between the posterior probability scores and 
the PAM50-derived cell proliferation score, particularly 
for the signatures associated with the late time points. 
Results from the correlation analyses are provided in 
supplementary table S3.
We next evaluated the prognostic performance of 
the gene signatures representing molecular changes either 
early or late during the acquisition of a motile or invasive 
cell phenotype. For each data set and each signature 
separately, a Kaplan-Meier analysis and univariate 
Cox regression analysis were performed. For the Cox 
UHJUHVVLRQ DQDO\VHV KD]DUG UDWLRV FRQ¿GHQFH LQWHUYDOV
7DEOH
Condition Delta (5/22&9 # genes Test ER Sensitivity 6SHFL¿FLW\
Early Migration 2.1 0% 271
Late Migration 3.1 0% 211
Early Invasion 2.7 0% 201 37% 83% 58%
Late Invasion 2.8 0% 255 37% 83% 58%
ER Error Rate 
/22&9/HDYH2QH2XW&URVV9DOLGDWLRQ
)LJXUH  ([SHULPHQWDO GHVLJQ IRU in vitro LVRODWLRQ
RI 51$ IURP PLJUDWRU\LQYDVLYH DQG UHIHUHQFH
SRSXODWLRQVA. After 24h of serum starvation, MDA-MB-231 
cells were seeded into Transwell inserts with (invasion) or 
without a layer of Matrigel (migration). At the indicated early 
and late time points, total RNA was isolated after direct lysis of 
the respective cell populations on the membranes. This procedure 
was performed in triplicate for each condition. B. Time point 
selection for RNA-isolation from migratory and invasive cells. 
'\QDPLFPLJUDWLRQOHIWDQGLQYDVLRQULJKWSUR¿OHVRI0'$
MB-231 cells have been generated by xCELLigence RTCA in 
correlating conditions with the Transwell experiments (panel 
A). Arrowheads indicate selected time points for RNA-isolation 
as described in panel A. Inset shows an integrated plot of the 
migration (blue graph) and invasion (red graph) patterns.
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and P-values are provided in supplementary table S3. In 
addition, Kaplan-Meier plots are provided in Figure 2A 
and forest plots in Figure 2B. In general, patients with 
tumors with enhanced migratory or invasive characteristics 
exhibit a reduced DMFS interval, independent of the 
evaluated time point. Univariate Cox regression analysis 
was then performed on the combined data set of 979 
VDPSOHV,QWKLVVHULHVZHREVHUYHGVLJQL¿FDQWO\UHGXFHG
DMFS intervals for patients bearing tumors that exhibit 
characteristics of migratory or invasive breast cancer cells, 
independent of the evaluated time point. Data are provided 
in supplementary table S3. In multivariate analysis, after a 
stepwise backward selection procedure, only the PAM50-
derived scores for luminal A or normal-like tumors 
UHPDLQHG VLJQL¿FDQW LQ DGGLWLRQ WR WKH3$0GHULYHG
score for cell proliferation.  
,GHQWL¿FDWLRQRI./)DVDSRWHQWLDOVXSSUHVVRU
RILQYDVLYHJURZWKLQEUHDVWFDQFHUFHOOV
The microarray-based gene expression studies 
revealed that KLF9 (also known as BTEB1) was 
VLJQL¿FDQWO\GRZQUHJXODWHGLQWKHLQYDVLYHVXESRSXODWLRQ
RI0'$0%FHOOV7KLV¿QGLQJKDVEHHQYDOLGDWHG
by RT-qPCR (Supplementary Fig 2) and possibly implies 
a suppressing capacity on breast cancer cell invasiveness. 
Therefore, we screened a panel of breast cancer cell lines 
for KLF9-expression using RT-qPCR. It was found that 
non-invasive cell lines (MCF-7, SKBR-3, T47D, ZR-75-1, 
&$0$DQG0'$0%VKRZHGVLJQL¿FDQWO\KLJKHU
levels of KLF9 mRNA when compared to invasive cell 
lines (MDA-MB-231 and MDA-MB-468) (Fig 3). 
)LJXUH*HQHVLJQDWXUHVIURPPLJUDWRU\DQGLQYDVLYHEUHDVWFDQFHUFHOOVLQGLFDWHUHGXFHG'0)6A. Kaplan-Meier 
survival analysis for four different gene signatures on four breast cancer gene expression datasets. Columns 1 – 2 represent the early 
and late migration signature, columns 3 – 4 the early and late invasion signature respectively. Rows 1 – 4 represent datasets GSE7390, 
GSE2034, GSE11121 and NKI295 respectively. Tumor samples have been dichotomized according to the degree of correlation with the 
UHVSHFWLYHVLJQDWXUHVEODFNJUDSKDQG!UHGJUDSK3YDOXHVDUHGHSLFWHGRQHDFKSORW%)RUWKHJHQHVLJQDWXUHVUHODWHG
to early migration, late migration, early invasion and late invasion forest plots were generated depicting the associations of each signature 
with DMFS per data set. The X-axis represent the hazard ratio obtained through cox regression analysis. The black square indicates the 
PDJQLWXGHRIWKHKD]DUGUDWLRDQGLVSURSRUWLRQDOWRWKHVDPSOHVL]HLQWKHFRUUHVSRQGLQJVWXG\7KHJUH\OLQHLQGLFDWHVWKHFRQ¿GHQFH
interval. The black diamond indicates a summary value estimated through meta-analysis using a random effects model. The width of the 
GLDPRQGLVSURSRUWLRQDOWRWKHFRQ¿GHQFHLQWHUYDO7KHGDVKHGYHUWLFDOJUH\OLQHLQGLFDWHVDKD]DUGUDWLRRIPHDQLQJQRDVVRFLDWLRQ
ZLWK'0)6&RQ¿GHQFHLQWHUYDOVFURVVLQJWKLVJUH\OLQHUHSUHVHQWQRQVLJQL¿FDQWKD]DUGUDWLRV
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To better address its role in breast cancer cell 
motility and invasion, KLF9 was overexpressed in MDA-
MB-231 cells by transient introduction of a pEGFP-KLF9 
fusion construct and a pEGFP plasmid in parallel serving 
DVFRQWURO([SUHVVLRQZDVFRQ¿UPHGE\ERWK57T3&5
LPPXQRÀXRUHVFHQFH DQG:HVWHUQ EORW )LJ $ % ,Q
addition, it must be noted that expression of the EGFP-
./)IXVLRQSURWHLQZDVVWULFWO\FRQ¿QHGWRWKHQXFOHXV
ZKHUHDV(*)3RQO\(9ZDV ORFDOL]HG LQQXFOHDUDQG
cytosolic areas (Fig 4C), indicating intact functionality of 
the fusion protein.
Introduction of EGFP-KLF9 induced a 
morphological switch in MDA-MB-231 cells after 
24h, leading to reduced spreading and the formation of 
dense zones of cortical actin (Fig 4C). As shown, MDA-
MB-231/EGFP cells maintained the wild-type spindle-
VKDSHG PRUSKRORJ\ 7KLV ¿QGLQJ KDV EHHQ FRQ¿UPHG
after 16 days of culturing in complete growth medium 
containing G418 selection antibiotic hereby enriching for 
MDA-MB-231/EGFP-KLF9 resp. MDA-MB-231/EGFP 
cell populations (Fig 4D).
Putative involvement of KLF9 in breast cancer cell 
invasion was assessed in vitro by conducting a series of 
Transwell experiments on transiently transfected MDA-
MB-231 cells after 24h. MDA-MB-231/EGFP-KLF9 cells 
VKRZHGDVLJQL¿FDQWO\GHFUHDVHGLQYDVLYHSRWHQWLDOZKHQ
FRPSDUHG WR0'$0%(*)3 3  0DQQ
Whitney U) (Fig 4E). 
KLF9LVGRZQUHJXODWHGLQEUHDVWWXPRUWLVVXH
To investigate the clinical relevance of the observed 
in vitro effects, the expression of KLF9 was assessed in 
normal human breast tissue and breast cancer. All breast 
cancer samples (N=22, mean age: 59 ± 13) showed a 
VLJQL¿FDQWO\GHFUHDVHGH[SUHVVLRQRIKLF9 in comparison 
with normal breast tissue (N=8, mean age: 45 ± 16) (Fig 
5A). 
2QFRPLQH ZZZRQFRPLQHFRP 2QFRPLQH
Research Premium Edition) [13] was searched for KLF9 in 
several expression data sets containing mixed normal and 
cancer samples. Next to loss of expression in 6 out of 16 
FDQFHUW\SHV6XSSOHPHQWDU\¿JXUH$KLF9 was shown 
WR EH VLJQL¿FDQWO\ GRZQUHJXODWHG LQ EUHDVW FDUFLQRPD
when compared to normal breast epithelium, applying P 
DQGIROGFKDQJHDVWKUHVKROGV6XSSOHPHQWDU\
¿JXUH %' 6XSSOHPHQWDU\ WDEOH 6  > @ DQG
TCGA Research Network). This was also found in data 
sets comparing invasive breast carcinoma with normal 
EUHDVWWLVVXH6XSSOHPHQWDU\¿JXUH()6XSSOHPHQWDU\
table S4) ([16] and TCGA Research Network). There 
was no correlation of KLF9-expression with ER-, PR- 
or HER2-status, implying that loss of expression of this 
transcription factor is a receptor-independent event in the 
malignant transformation of mammary epithelial cells. 
Additionally, an inverse correlation was found 
between KLF9-expression and the Mitotic Activity Index 
(MAI) in the series of breast cancer samples (Fig 5B), 
implying an anti-proliferative effect of KLF9. In vitro, 
upregulation of KLF9 expression was shown in MDA-
0% FHOOV LQ D FRQÀXHQF\GHSHQGHQW PDQQHU ZLWK
OLPLWHGH[SUHVVLRQLQVXEFRQÀXHQWFXOWXUHV
and a 3-fold rise of KLF9P51$LQFRQÀXHQWFXOWXUHV
FRUURERUDWLQJWKH¿QGLQJVLQFOLQLFDOVDPSOHV)LJ&
DISCUSSION
This report describes the assessment of gene 
expression characteristics associated with breast 
cancer cells in two different phases during migration 
and invasion. It has become clear that a high degree of 
heterogeneity exists both between (inter-tumoral) and 
within (intra-tumoral) individual breast tumors [17]. It has 
already been established that, within a clinically invasive 
tumor, not all tumor cells will become invasive and that 
invasive behavior is regulated spatio-temporally by the 
microenvironment [10]. The molecular characterization 
of cancer cell migration and invasion by genome-wide 
JHQH H[SUHVVLRQ SUR¿OLQJ LV ODUJHO\ LPSHGHG E\ WKHVH
IHDWXUHV:KHQ REWDLQLQJ PLFURDUUD\EDVHG SUR¿OHV RI
FHOOVH[SRVHGWRFKHPRWDFWLFFXHVWKHH[SUHVVLRQSUR¿OH
of the motile / invasive subpopulation of interest is masked 
by non-responsive cells constituting the majority of the 
cell population [6]. The triple negative MDA-MB-231 
)LJXUHKLF9 LVGRZQUHJXODWHGLQLQYDVLYHFHOOOLQHV
Non-invasive breast cancer cell lines show higher expression 
levels of KLF9 mRNA than invasive cell lines. Results from 
Transwell Matrigel invasion experiments are shown in red (left 
axis), accompanied by micrographs of representative crystal 
violet-stained membranes (obj. 20X) per cell line mentioned 
below. All experiments have been performed in technical and 
biological triplicates. Normalized relative expression levels 
for KLF9 as measured by RT-qPCR are shown in green (right 
axis). All RT-qPCR experiments have been performed in at least 
technical duplicates and biological triplicates.  All results shown 
are means + SD.
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)LJXUH)RUFHGH[SUHVVLRQRIKLF9DOWHUVFHOOPRUSKRORJ\DQGLPSDLUVEUHDVWFDQFHUFHOOLQYDVLRQ
$Normalized relative expression levels of KLF9 in transiently transfected MDA-MB-231/KLF9DQG0'$0%(9FHOOVKSRVW
WUDQVIHFWLRQ,QVHWVKRZVGHWDLOHGUHVXOWVIRU0'$0%(9PRFNWUDQVIHFWHGDQGZLOGW\SH0'$0%5HVXOWVVKRZQDUHPHDQV
± SD of three replicates. 
%Western blot analysis for expression of EGFP-KLF9 fusion protein in MDA-MB-231 cells, transfected with either KLF9RU(9/\VDWHV
were prepared 24h after transfection. 
&F-actin staining of MDA-MB-231/KLF9DQG(9XVLQJSKDOORLGLQ75,7&(9WUDQVIHFWHGFHOOVUHFRQVWLWXWHWKHVSLQGOHOLNHPRUSKRORJ\
RIZLOGW\SH0'$0%FHOOV(9VKRZVERWKQXFOHDUDQGF\WRVROLFORFDOL]DWLRQ(*)3JUHHQ3KDOORLGLQVWDLQHGDFWLQUHGLQGLFDWHV
changes in cell morphology in KLF9DQG(9H[SUHVVLQJFHOOV%DUVP
' 3KDVH FRQWUDVW OHIW FROXPQ DQG ÀXRUHVFHQFH LPDJHV ULJKW FROXPQ RI 0'$0%KLF9 WRS URZ DQG (9 ERWWRP URZ
respectively. Pictures were taken after 16 days of culturing in the presence of G418 selection antibiotic for enrichment of transfected cells. 
KLF9-expressing MDA-MB-231 cells (top row) are incapable of reconstituting the wild-type morphology. Arrows indicate examples of 
cells expressing KLF9%DUVPWRSURZDQGPERWWRPURZ
(Transwell-based Matrigel invasion experiments revealed impairment of MDA-MB-231 invasion in the presence of KLF9. Results 
VKRZQDUHPHDQFHOOFRXQWV6'IURPWKUHHLQGHSHQGHQWH[SHULPHQWVLQDWOHDVWH[SHULPHQWDOWULSOLFDWHV30DQQ:KLWQH\8
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cell line is able to spontaneously metastasize in orthotopic 
mice models and, therefore, represents a suitable model 
to detect gene expression changes associated with the 
early steps of metastatic dissemination [18]. In the 
present study, a Transwell-based design was adopted in 
order to capture the gene expression characteristics of the 
migrated/invaded subpopulation, physically separated 
from the non-migratory / non-invasive majority of cells. 
Furthermore, two time points have been selected to 
distinguish gene expression patterns in an early and a late 
phase and invasion and migration have been regarded as 
distinct processes in vitro. Differential gene expression 
and pathway analysis revealed that the invaded and 
migrated subpopulations were, next to processes of cell 
PRYHPHQWKLJKO\HQULFKHGLQUHSOLFDWLYHLQÀDPPDWRU\
and developmental programs. In addition, it was found 
that both invaded and migrated subpopulations showed 
VLJQL¿FDQWO\ XSUHJXODWHG '1$ GDPDJH UHSDLU DFWLYLW\
VXSSOHPHQWDU\¿J7KHVH¿QGLQJVFRUUHODWHZLWKUHVXOWV
of a recent study with a similar rationale, conducted in vivo 
using the same cell line [18]. Moreover, in concordance 
with Patsialou et al., invaded cells showed increased 
7*)VLJQDOLQJ LQ WKH HDUO\ SKDVH ZLWKRXW VLJQL¿FDQW
detection of TGFß itself and upregulation of CDC25A, a 
gene associated with tumorigenesis [19]. 
The gene expression signatures, corresponding with 
migrated and invaded cells in the late phase, consequently 
predicted reduced DMFS for the four expression 
datasets, comprising in total nearby 1000 breast tumors. 
The positive correlations with the PAM50-derived cell 
proliferation score obtained for the late-phase signatures, 
however, indicate proliferation to remain a driver in the 
prognostic ability, even though motility and invasion were 
the experimental foci in this study.
1HYHUWKHOHVV WKH LGHQWL¿FDWLRQ RIKLF9 and the 
initial results showing its inhibitory effect on cancer 
cell invasion, corroborated by its differential expression 
between invasive and non-invasive cell lines, imply 
interactions between proliferation- and invasion-mediating 
programs. KLFs form a family of highly conserved 
]LQF ¿QJHU WUDQVFULSWLRQ IDFWRUV ZLWK YHUVDWLOH UROHV LQ
proliferation, differentiation and development [20]. Apart 
from KLF9, our data also demonstrate downregulation of 
KLF4 and KLF6 in the early invaded and late migrated 
subpopulations respectively. To date, KLF4 is the most 
extensively described member of the family, not in the 
least for its contribution to pluripotent stem cell induction 
[21]. In cancer biology, the effect of KLFs has been found 
to be context-dependent, with both tumor suppressing and 
oncogenic roles reported for breast cancer [22-24]. This 
duality could, at least partly, be explained through altered 
genetic backgrounds appearing in transforming epithelial 
cells [25]. Altogether, the most recent reports point 
towards KLF4 as a tumor suppressor, being downregulated 
in human breast cancer samples. Additionally, a promoting 
interaction between KLF4 and CDH1 (E-cadherin) has 
been described, hereby driving cancer cells into an EMT-
program through loss of KLF4 [23]. A similar effect was 
found to be exerted through downregulation of KLF17 
[26]. KLF6 has been reported as a tumor suppressor in 
prostate cancer [27] and recently a splice variant thereof, 
./)69 ZDV LGHQWL¿HG DV DQ RQFRJHQH LQ EUHDVW
cancer with increased expression in breast tumors [28]. 
2XU ¿QGLQJV VXSSRUW WKHVH UHVXOWV VKRZLQJ ORVV RI
expression of these KLFs in migratory / invasive breast 
cancer cells, and illustrate the complexity of their role in 
tumor development and progression. Reports on the role 
of KLF9 are thus far limited to colon and endometrial 
carcinoma. Reduced expression of KLF9 has been shown 
on a transcriptional as well as protein level in colorectal 
cancer samples when compared to paired normal mucosa 
[29]. Similarly, endometrial carcinomas also demonstrated 
lower levels of KLF9 when normal endometrium and stage 
,GLVHDVHZHUHFRPSDUHGZLWKVWDJH,,±,9FDUFLQRPDV,Q
this tumor type, downstream repression of regulators of 
the actin cytoskeleton has been detected by microarray in 
PRGL¿HGFHOOOLQHVRYHUH[SUHVVLQJKLF9 >@2XUUHVXOWV
SURYLGH WKH ¿UVW HYLGHQFH RIKLF9 as a suppressor of 
)LJXUH  KLF9 LV GRZQUHJXODWHG LQ KXPDQ EUHDVW
FDQFHU
$Scatter plot depicting normalized relative expression levels of 
KLF9 as detected by RT-qPCR in normal human breast samples 
(N=8) and breast cancer (N=22). Horizontal lines indicate the 
PHDQOHYHORIH[SUHVVLRQSHUJURXS3
%Correlation plot showing available mitotic activity indices 
(MAI), as assessed at diagnosis for each patient (N=18), in 
relationship to the normalized expression of KLF9 per sample.
&Normalized relative expression levels of KLF9, as detected 
by RT-qPCR in triplicates, in wild-type MDA-MB-231 cells at 
GLIIHUHQWGHJUHHVRIFRQÀXHQF\ LQFXOWXUH LOOXVWUDWHGE\SKDVH
FRQWUDVWSLFWXUHVEHORZHDFKGHJUHH%DUVP
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invasive growth in breast carcinoma. The loss of KLF9, as 
IRXQGLQVHYHUDO2QFRPLQHEUHDVWGDWDVHWVDQGLQDVHULHV
RIEUHDVWVDPSOHVIURPRXULQVWLWXWLRQFRQ¿UPWKHFOLQLFDO
relevance of this transcription factor in human breast 
cancer. The inverse relationship of KLF9 with mitotic 
activity and the contact inhibition-driven upregulation 
of KLF9 in culture, imply a role in cell cycle regulation, 
which has also been demonstrated for KLF4 [31]. Whether 
the reduced expression of KLF9 in invaded MDA-MB-231 
cells in comparison with their non-invasive counterparts 
is an effect of active transcriptional or translational 
repression or due to the presence of a “KLF9low”-
subpopulation within the general cell population remains 
to be investigated.
2XU GDWD VHW GHULYHG IURP LQYDGHG EUHDVW FDQFHU
FHOOVDOVRUHYHDOHGDVLJQL¿FDQWGRZQUHJXODWLRQRI(
like factor 3 (ELF3). ELF5, a transcriptional regulator 
closely related to ELF3KDVUHFHQWO\EHHQLGHQWL¿HGDV
a suppressor of EMT in MDA-MB-231 cells by direct 
repression of SNAI2. In addition, ELF5-expression was 
strongly reduced in breast cancer samples [32].  Also 
recently, leukemia inhibitory factor receptor (LIFR), a 
gene present in our prognostic invasion signature, was 
found to exert anti-metastatic effects through activation 
of the Hippo pathway and functional inactivation of the 
transcriptional co-activator YAP$VLJQL¿FDQWDVVRFLDWLRQ
between loss of LIFR and poor prognosis in breast cancer 
has been discovered as well [33]. Indeed, our data from 
LVRODWHGLQYDGHG0'$0%FHOOVUHYHDODVLJQL¿FDQW
downregulation of LIFR, in support of these recent results. 
In conclusion, our data provide novel insights on 
cell migration and invasion as separate and initiating 
processes in the invasion-metastasis cascade. The devised 
in vitro experimental design has yielded prognostic gene 
VLJQDWXUHVLQGLFDWLQJUHGXFHG'0)6LGHQWL¿HGKLF9 as 
a novel potential invasive growth suppressor in breast 
cancer and generated results in concordance with previous 
VWXGLHV*HQH H[SUHVVLRQ SUR¿OLQJ KDV LQGHHG UHYHDOHG
migration and invasion as highly related, yet different 
processes. Furthermore, according to our results, the 
role of proliferation, DNA damage repair mechanisms 
and cell motility programs should not be considered 
as mutually exclusive. We believe that the consistent 
subtype-independent downregulation of KLF9 in patient 
PDWHULDOFRQ¿UPVWKHUHOHYDQFHRIWKLVIDFWRULQKXPDQ
breast cancer. Finally, the complex interplay of KLF9 with 
its related family members in breast cancer, and epithelial 
cancer biology in general, still remains largely elusive and 
needs to be thoroughly investigated in order to identify 
downstream genes as potential therapeutic targets or 
mediators of metastatic progression.
0$7(5,$/6$1'0(7+2'6
&HOOFXOWXUH
The MDA-MB-231, MCF-7, CAMA-1 and ZR-75-1 
cells were cultured in RPMI1640, MDA-MB-468 cells in 
DMEM/F12, MDA-MB-361 and T47D cells in DMEM 
and SKBR-3 cells in McCoy’s 5A media, all supplemented 
with 10% fetal bovine serum (FBS), 1% L-glutamine, 
1% penicillin/streptomycin and 1% sodium pyruvate. 
All cell culture reagents were purchased from Invitrogen 
(Life Technologies, USA) unless mentioned otherwise. 
&HOOOLQHVZHUHPDLQWDLQHGDW&DQG&22/95% air 
LQDKXPLGL¿HGLQFXEDWRU0'$0%DQG&$0$
were kindly provided by Dr. Maurice PHM Jansen and 
'U-RKQ:00DUWHQV'HSDUWPHQWRI0HGLFDO2QFRORJ\
Erasmus University Medical Center, Daniel den Hoed 
Cancer Center, Rotterdam, The Netherlands). Although 
the MDA-MB-231, MDA-MB-468, MCF-7 and SKBR-
3 breast cancer cell lines have been purchased from the 
American Type Culture Collection (ATCC, USA) (http://
www.lgcstandards-atcc.org), all cell lines have been 
YDOLGDWHGLQKRXVHE\VKRUWWDQGHPUHSHDW675SUR¿OLQJ
using the Cell ID™ System (Promega, USA) according to 
the manufacturer’s instructions. 
xCELLigence UHDOWLPHFHOODQDO\VLV57&$
Real-time cell migration and invasion experiments 
were performed on an xCELLigence RTCA DP instrument 
(ACEA Biosciences, USA) as described previously [34]. 
%ULHÀ\[5 MDA-MB-231 cells were seeded on top of 
DVROLGL¿HG0DWULJHOOD\HUYYLQNLQHWLFFRUUHODWLRQ
with 4x105 cells on 20% (v/v) Matrigel in a conventional 
Transwell system [34]. Cells were allowed to invade 
during 50h with kinetic measurements programmed every 
15 minutes to display dynamic invasive behavior patterns 
at the above mentioned cell and Matrigel densities. Cell 
migration experiments were carried out as described 
above, without application of Matrigel.
7UDQVZHOOLQYDVLRQDQGPLJUDWLRQDVVD\
0LJUDWLRQDQG LQYDVLRQ VHWXS IRU51$LVRODWLRQRI
GLVWLQFWFHOOSRSXODWLRQV
In vitro invasion experiments have been performed 
using a conventional 24-well Transwell system 
(Corning®), essentially as described previously [34], 
with 4x105 cells seeded on top of a 20% (v/v) Matrigel 
layer. Complete medium was added to the wells as 
chemoattractant and the Transwell plates were incubated 
DW&&22GXULQJK¿UVWWLPHZLQGRZDQGK
(second timewindow), as predetermined in real-time 
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invasion assessments. 
An identical protocol as the above was followed 
for migration experiments, without application of an 
extracellular matrix substitute. Transwell migration plates 
ZHUHLQFXEDWHGGXULQJK¶¿UVWWLPHZLQGRZDQGK
(second timewindow). For both invasion and migration, 
the respective timeframes of incubation have immediately 
been followed by RNA-isolation.
0LJUDWLRQDQGLQYDVLRQDVVHVVPHQWRIZLOGW\SHDQG
WUDQVIHFWHGFHOOOLQHV
Cell line Transwell migration and invasion 
experiments were performed essentially as described 
DERYHZLWK WKH IROORZLQJ VSHFL¿FDWLRQV IRU WUDQVIHFWHG
cell lines: 24h after transfection, 105 cells were seeded 
in the inserts after 4h serum starvation. Both invasion 
DQGPLJUDWLRQZHUHTXDQWL¿HGDIWHUKE\FHOOFRXQWLQJ
LQ DW OHDVW WKUHH GLIIHUHQW ¿HOGV SHU PHPEUDQH DW
;PDJQL¿FDWLRQ (DFK FRQGLWLRQ ZDV SHUIRUPHG LQ
technical and biological triplicates.
51$LVRODWLRQ IURP LQYDVLYH DQG PLJUDWRU\
VXESRSXODWLRQVDQGPLFURDUUD\K\EULGL]DWLRQ
Total RNA was extracted using the RNAqueous™ 
Micro Kit (Life Technologies, USA) for nucleic acid 
extraction from small cell populations. All cell populations 
of interest were lysed directly on the membranes 
without prior enzymatic detachment. Isolated RNA was 
immediately tested on yield, purity and quality using 
D 1DQR'URS 1' 7KHUPR 6FLHQWL¿F 86$
and a BioAnalyzer 2100 (Agilent Technologies, USA) 
device. Samples were stored at -80°C and only samples 
with absorption (A) ratios A260/A280DQG$260/A230 
 1DQR'URSDQG51$,QWHJULW\1XPEHU 5,1
> 6 (BioAnalyzer) were considered for microarray 
hybridization.  
3ULRUWRK\EULGL]DWLRQ51$VDPSOHVZHUHDPSOL¿HG
XVLQJWKH,OOXPLQD7RWDOSUHS51$$PSOL¿FDWLRQNLW/LIH
Technologies, USA). Subsequently, single-stranded cRNA 
with incorporated biotin-UTP nucleotides was produced 
by an in vitro transcription reaction and hybridized onto 
an Illumina Human HT-12 v4 gene expression BeadChip. 
Three biological replicates per time point per biological 
state were loaded, totalling 24 sample hybridizations 
on two chips. After overnight sample hybridization, 
subsequent washing steps and sample labeling, intensity 
values were read on an Illumina iScan equipped with iScan 
control software (v. 3.3.29). All microarray expression 
GDWDKDYHEHHQGHSRVLWHGLQWKH*HQH([SUHVVLRQ2PQLEXV
database (http://www.ncbi.nlm.nih.gov/geo/) under the 
accession number GSE54465.
51$LVRODWLRQIURPFHOOOLQHVDQGFOLQLFDOVDPSOHV
Cell line total RNA was extracted using the 
TRIzol® method (Life Technologies, USA) after lysis of 
VXEFRQÀXHQWFXOWXUHV LQFP2 FXOWXUHÀDVNV 7$V
mentioned above, yield and purity of the isolates were 
tested using a NanoDrop® system and stored at -80°C.
)URP HYHU\ FOLQLFDO VDPSOH  PVHFWLRQV
were made and stored in cryotubes (-80°C) for RNA-
extraction. RNA was extracted from the samples using the 
RNeasy Lipid Tissue Mini Kit (Qiagen, Germany).
0LFURDUUD\GDWDDQDO\VLV
All microarray data analysis procedures were 
performed using BioConductor in R (v 2.13.0). Raw 
intensity reading, log2-transformation, summarization, 
quantile normalization and quality controls were 
performed using the methods implemented in the 
BioConductor package “beadarray” (v 2.8.1) [35]. 
Normalized expression data were further analysed using 
the package “limma” (v 3.14.4) [36] to identify lists of 
differentially expressed genes between the migratory 
or invasive cell populations on the one hand and their 
respective controls on the other hand. Lists of differentially 
expressed genes were then functionally annotated by 
DQDO\]LQJ WKHP IRU HQULFKHG*HQH2QWRORJ\ *2 DQG
Kyoto Encyclopedia of Genes and Genomes (KEGG) 
categories through hypergeometric Gene Set Enrichment 
Analysis (GSEA). In addition, Ingenuity Pathway Analysis 
(IPA) software was used for similar purposes. For all 
analyses, correction for multiple testing was performed 
using the Benjamini and Hochberg step-up false discovery 
rate (FDR) controlling procedure and adjusted P-values 
LQIHULRUWRZHUHFRQVLGHUHGVLJQL¿FDQW
To identify gene signatures (N=4) representing 
molecular changes occurring either early or late during 
the acquisition of a motile or invasive cell phenotype, the 
nearest shrunken centroid-algorithm, implemented in the 
BioConductor-package Prediction Analysis of Microarrays 
IRU53$05ZDVDSSOLHG8VLQJ/HDYH2QH2XW&URVV
YDOLGDWLRQ /22&9DįYDOXH WKDWFRUUHVSRQGV WR WKH
lowest cross-validated error rate, was selected. This 
įYDOXH GH¿QHV D OLVW RI SUHGLFWRU JHQHV IRUZKLFK WKH
minimal expression difference between the invasive or 
PRWLOHFHOOSRSXODWLRQVDQGWKHLUFRQWUROVHTXDOVį7KH
WKXVLGHQWL¿HGOLVWVRISUHGLFWRUJHQHVGHWHUPLQHFHQWURLGV
that can be used to classify patient samples according to 
the presence or absence of motile or invasive cancer cell 
characteristics. 
To determine the clinical relevance of our gene 
signatures, we analyzed four publicly available gene 
expression series from patients with breast cancer with 
documented follow-up in terms of distant metastasis-
IUHH VXUYLYDO '0)6 *6( >@ *6( >@
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GSE11121 [39] and NKI295 [40]). To ensure proper 
FODVVL¿FDWLRQSHUIRUPDQFHZHXVHGWKH³OLPPD´SDFNDJH
WR QRUPDOL]H HDFK GDWD VHW 6DPSOH FODVVL¿FDWLRQ ZDV
WKHQ SHUIRUPHG E\ FRPSDULQJ WKH VLJQDWXUHVSHFL¿F
H[SUHVVLRQ SUR¿OHV RI HDFK VDPSOH ZLWK HDFK RI WKH
LGHQWL¿HG FHQWURLGV ,Q WKLV SURFHVV HDFK VDPSOH LV
assigned a posterior class probability, a value ranging 
IURPWRLQGLFDWLQJWKHVWUHQJWKRIWKHFODVVL¿FDWLRQ,Q
DGGLWLRQHDFKVDPSOHLQWKHVHSDWLHQWVHULHVZDVFODVVL¿HG
according to the molecular subtypes using the PAM50-
algorithm [41]. 
6XUYLYDODQDO\VLV
To evaluate the prognostic performance of the 
gene signatures, we performed Kaplan-Meier and Cox 
regression analysis using DMFS as endpoint. All analyses 
were performed using the R-package “survival” (v 
2.36.5). Kaplan-Meier analysis was performed using the 
GLFKRWRPL]HG FODVVL¿FDWLRQ UHVXOWV LH LQYDVLYHQRQ
invasive or motile/non-motile). Univariate Cox regression 
analysis was performed using the posterior class 
SUREDELOLWLHVIRUHDFKRIWKHLGHQWL¿HGJHQHVLJQDWXUHVDQG
all parameters (i.e. molecular subtypes and the measures 
for cell proliferation, ER-activation and ErbB2-activation) 
provided by the PAM50-algorithm. Multivariate Cox 
regression analysis was then performed for each variable 
LGHQWL¿HGDVVLJQL¿FDQWLQWKHXQLYDULDWHVHWWLQJ
&OLQLFDOVDPSOHV
The clinical breast tumor and reference normal 
tissue samples used in this publication were provided 
by the UZA tumor bank, Antwerp University Hospital, 
Belgium. The samples were stored at -80°C. In each case 
RQHPVHFWLRQZDVPDGHXVLQJDFU\RWRPH7KHUPR
6FLHQWL¿F 86$ ZKLFK ZDV +( VWDLQHG 7KHUPR
6FLHQWL¿F86$$OOVDPSOHGLDJQRVHVZHUHYDOLGDWHGE\
a trained pathologist, considering only samples without 
necrosis and, for tumor samples, a tumor/stroma ration 
of minimum 40%. The Mitotic Activity Index (MAI) was 
calculated as the average number of mitotic spindles per 
mm2FRXQWHGLQGLIIHUHQWKLJKSRZHU¿HOGV
F'1$V\QWKHVLVDQGUHDOWLPHTXDQWLWDWLYH3&5
0LFURDUUD\YDOLGDWLRQ
Reverse transcription quantitative PCR (RT-
qPCR) was performed on total RNA in a single reaction 
using the Power SYBR Green RNA-To-CT 1-Step 
kit (Life Technologies, USA) on a LightCycler 480 
instrument (Roche Applied Science, Germany). Primers 
were designed using QuantPrime software [42] and 
RTPrimerDB (http://www.rtprimerdb.org) [43] and 
have been obtained from Integrated DNA Technologies 
(USA) (supplementary table S5). All reactions have been 
SHUIRUPHGLQWULSOLFDWHVLQZHOOSODWHVZLWK/51$
SUHGLOXWHGWRQJ/DVLQSXWLQDWRWDOUHDFWLRQYROXPH
RI / IXUWKHU FRPSULVLQJ / 3RZHU 6<%5*UHHQ
573&50L[[/LIH7HFKQRORJLHV86$/57
Enzyme Mix (125x) (Life Technologies, USA) and 200nM 
RIHDFKSULPHU¿QDOFRQFHQWUDWLRQ1RUPDOL]HGUHODWLYH
gene expression values were calculated using qBasePLUS 
software version 1.5 (Biogazelle) [44]. 
&HOOOLQHH[SUHVVLRQOHYHOVRI./)
All reactions have been performed following the 
above described protocol using identical primer pairs. 
SDHA, RPL13A and HMBS ZHUH LGHQWL¿HG DV VWDEO\
expressed across all analyzed cell lines and have been used 
as reference genes to determine relative KLF9 expression 
levels in triplicate.
([SUHVVLRQOHYHOVRI./)LQEUHDVWWXPRUWLVVXH
All RT-qPCR experiments were performed as 
indicated above. SF3A1 and YWHAZZHUHLGHQWL¿HGDV
being stably expressed in tumor as well as normal tissue 
samples. Expression levels of KLF9 were calculated using 
qBasePLUS v1.5.
0ROHFXODUFORQLQJDQGWUDQVIHFWLRQ
7KH25)RI:7KLF9 was cloned in a pEGFP-N1 
backbone, with subsequent bi-directional sequencing on an 
ABI 3130xL (Life Technologies, USA). Next, expression 
vectors were electroporated into MDA-MB-231 cells using 
D1XFOHRIHFWRU,,GHYLFH/RQ]D6ZLW]HUODQG%ULHÀ\6 
FHOOVZHUHFROOHFWHGIURPDVXEFRQÀXHQWFXOWXUH
electroporated with plasmid DNA and seeded into 6-well 
plates. After overnight settlement, growth medium was 
replaced and experiments initiated after 24h. 
To obtain stable cell populations, enrichment for 
EGFP-KLF9 or EGFP expressing cells was obtained 
WKURXJK DGGLWLRQ RI * DQWLELRWLF JP/ /LIH
Technologies, USA) to the growth medium starting 24h 
after transfection and renewed every 48h. 
)OXRUHVFHQFHPLFURVFRS\
&HOOV ZHUH ¿[HG LQ  SDUDIRUPDOGHK\GH
permeabilized in 0.1% Triton-X-100, blocked in 1% BSA, 
stained with phalloidin-TRITC (Sigma Aldrich, USA) and 
PRXQWHGRQWRJODVVVOLGHVXVLQJ9HFWDVKLHOG+DUG6HW
0RXQWLQJ0HGLXP9HFWRU/DERUDWRULHV86$FRQWDLQLQJ
'$3,DVQXFOHDU FRXQWHUVWDLQ9LVXDOL]DWLRQDQG LPDJH
FDSWXULQJKDYHEHHQSHUIRUPHGRQDQ(926)/&HOO
Imaging System (Life Technologies, USA). 
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Whole-cell lysates have been prepared using RIPA 
buffer containing protease-inhibitors (Roche Diagnostics 
GmbH, Germany). Protein concentration was determined 
XVLQJWKH%&$SURWHLQDVVD\NLW7KHUPR6FLHQWL¿F
:LOPLQJWRQ '( 86$ 7ZHQW\ J RI SURWHLQV ZHUH
loaded and separated by SDS-PAGE (Life Technologies, 
USA) on a 12% gel. Blots were incubated overnight 
with primary antibodies against KLF9 (Santa Cruz 
Biotechnology, USA) or EGFP (Sigma-Aldrich, USA). 
After incubation with a secondary IgG-HRP antibody 
(Santa Cruz Biotechnology, USA) and addition of HRP-
substrate (Lonza, Switzerland), proteins were visualized 
by chemiluminiscence. 
6WDWLVWLFDODQDO\VLV
All statistical analyses, except those related 
to microarray-based gene expression analyses, were 
performed in SPSS 21.0. A P-value below 0.05 was 
FRQVLGHUHG WR EH VWDWLVWLFDOO\ VLJQL¿FDQW  3 
33
Detailed methods and associated references 
are available in the Supplementary Information 
(Supplementary methods). 
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